Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Two loss years in a row NBB
Negative result in 2023 and 2024.
-
Tight liquidity NBB
Cash and receivables cover 45 % of short-term debt in 2024; threshold 65 %.
-
Busy address KBO
28 other companies have their registered office at the same address; threshold 10.
Financials
Financial year 2024
C-Biotech from Temse, company number BE0794909852, closed financial year 2024 with a result of € -628,639 after tax. For that financial year C-Biotech recorded revenue of € 97,133 and equity of € 194,724. Compared with financial year 2023, the result moved from € -431,266 to € -628,639. The company made a loss. The buffer is growing. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on June 27, 2025.
€ 194,724
▲ € 623,990 vs 2023
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -628,639
▼ 46 % more loss than in 2023
Profit after tax over the fiscal year.
€ 615,584
▲ € 579,596 vs 2023
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € -1.1 million.
People and assets in 2024
1.8
Average over the fiscal year, from the social balance sheet.
€ 107,250
€ 59,600 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
Debts at end 2024
€ 600,000
Loans from banks and other lenders, long and short.
€ 438,616
▲ 68% vs 2023
Supplier invoices still open on the last day of the fiscal year.
€ 11,574
Wages, holiday pay and social contributions still to pay. No outstanding taxes.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2023 | 2024 | Change 2023 → 2024 | |
|---|---|---|---|
| Revenue | € 119,611 | € 97,133 | ▼ 19% |
| Gross margin | € -410,262 | € -436,301 | ▼ € 26,038 |
| Profit after taxes | € -431,266 | € -628,639 | ▼ € 197,373 |
| Equity | € -429,266 | € 194,724 | ▲ € 623,990 |
| Total debts | € 788,508 | € 2,476,288 | ▲ 214% |
| Cash | € 35,988 | € 615,584 | ▲ € 579,596 |
| Retained profit | € -431,266 | € -1,059,906 | ▼ € 628,639 |
| Bank debt | € 0 | € 600,000 | |
| Balance sheet total | € 359,242 | € 2,671,012 | ▲ € 2.3 million |
| Employees (FTE) | 0 | 1.8 |
Key figures of C-Biotech, fiscal years 2023 to 2024, from the annual accounts filed with the National Bank of Belgium.The annual account for fiscal year 2025 has not been filed yet; it was expected before 31 July 2026.
What happened to C-Biotech?
What happened at C-Biotech in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2024: loss of € 628,639. Source: NBB ↗
- Bert Weemaes BV became a director. NBB
- Nova LaGa BV stepped down as director. NBB
- New establishment in Assesse. KBO
- New establishment in Temse. KBO
- Storm, Wolf & Partners CommV. became a director. NBB
- Nova LaGa BV became a director. NBB
- Start of the company according to the CBE. KBO
In short
From € 431,266 loss in 2023 to € 628,639 loss in 2024.
A new publication or filing at C-Biotech? We notify you, reason included.
Follow C-BiotechDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
The stake of FINO comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.
C-BiotechBehind C-Biotech are Bert Weemaes BV and Storm, Wolf & Partners CommV.. The shares are held by FINO (50%).
Directors
According to the 2024 annual accounts
Director · represented by Weemaes BERT
Also active at: IMTECH BELGIE, C-Tech Holding, C-LIVING, IMMO MOTCHES, VITA HORECA TEMSE, CORDEEL GROUP, BERNARD CONSTRUCTION, DEMCOR +41 more
since 2025
Director · represented by Verstraete FREDERIK
since 2022
Director · represented by Gacoin LAURENCE
Also active at: C-FIRE, C-LIVING, SOBELTEC, IMMO MOTCHES, C-Energy, VITA HORECA TEMSE, CORDEEL GROUP, VLAECO +36 more
since 2022 · until 2025
Shareholders
50%
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Frank Van Dyckelaan 15
9140 Temse
Rue du Bois-Gilot 2
5336 Assesse
Active since 29 November 2023
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 28 companies are registered at this address.
All companies at this address →C-FIRE same network
€ 535,397 gross margin · 2025
C-LIVING same network
€ 3.3 million revenue · 2025
C-Energy same network
€ 1 million gross margin · 2025
CORDEEL GROUP same network
€ 10 million revenue · 2025
C-Ground same network
€ -1.5 million gross margin · 2025
+23 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0794.909.852
- VAT number
- BE 0794.909.852
- Registered office
- Frank Van Dyckelaan 15, 9140 Temse
- Names & denominations
- C-Biotech
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 16 December 2022
- Peppol
- Active · Active since 1 Jan 2001
- Activities · NACE
Sanering en ander afvalbeheer